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Background: LVAD speed adjustment according to a functioning aortic valve has hypothetic advantages but could
lead to submaximal support. The consequences of an open aortic valve policy on exercise capacity and
hemodynamics have not yet been investigated systematically.
Methods: Ambulatory patients under LVAD support (INCOR®, Berlin Heart, mean support time 465 ± 257 days,
average flow 4.0 ± 0.3 L/min) adjusted to maintain a near normal aortic valve function underwent maximal
cardiopulmonary exercise testing (CPET) and right heart catheterization (RHC) at rest and during constant work rate
exercise (20 Watt).
Results: Although patients (n = 8, mean age 45 ± 13 years) were in NYHA class 2, maximum work-load and peak
oxygen uptake on CPET were markedly reduced with 69 ± 13 Watts (35% predicted) and 12 ± 2 mL/min/kg (38%
predicted), respectively. All patients showed a typical cardiac limitation pattern and severe ventilatory inefficiency
with a slope of ventilation to carbon dioxide output of 42 ± 12. On RHC, patients showed an exercise-induced
increase of mean pulmonary artery pressure (from 16 ± 2.4 to 27 ± 2.8 mmHg, p < 0.001), pulmonary artery wedge
pressure (from 9 ± 3.3 to 17 ± 5.3 mmHg, p = 0.01), and cardiac output (from 4.7 ± 0.5 to 6.2 ± 1.0 L/min, p = 0.008)
with a corresponding slight increase of pulmonary vascular resistance (from 117 ± 35.4 to 125 ± 35.1 dyn*sec*cm−5,
p = 0.58) and a decrease of mixed venous oxygen saturation (from 58 ± 6 to 32 ± 9%, p < 0.001).
Conclusion: An open aortic valve strategy leads to impaired exercise capacity and hemodynamics, which is not
reflected by NYHA-class. Unknown compensatory mechanisms can be suspected. Further studies comparing higher
vs. lower support are needed for optimization of LVAD adjustment strategies.
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Left ventricular assist devices (LVAD) are a proved bridge-
to-transplantation, and are increasingly utilized as long
term support devices for destination therapy [1,2]. Newer
generation continuous flow devices (cfLVAD) are charac-
terized by increased durability and suitability for longer
support intervals [3]. Currently, there is a debate about
the appropriate degree of support. In theory, the max-
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unless otherwise stated.hemodynamic stability, but also increases cardiopulmo-
nary performance. However, full support enhances left
ventricular unloading causing presumably more blood
damage, dangerous negative intraventricular pressures
and hazardous support limitations such as pump stops
with an increased risk of thrombus formation. In addition,
maximum support increases the pressure over the aortic
valve aggravating the development of aortic valve closure,
leaflet fusion, valve thrombosis or/and ultimately aortic re-
gurgitation, which seems to be a particular problem in pa-
tients with a closed aortic valve on long term support
[4-6]. Therefore it seems advisable to perform serial echo-
cardiographic exams to optimize pump speed with regard
to normal aortic valve function [7]. The hemodynamic
and exercise capabilities following this speed approach areal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(CPET) and right heart catheterization (RHC) studies dur-
ing exercise on support is limited [8,9], and the majority
of these studies focused on the exercise capabilities of
LVAD patients without emphasizing a normal aortic valve
function. To our knowledge, no data exists describing ex-
ercise performance of patients with optimized pump
speed with regard to a normal or near normal aortic valve
physiology on long-term support (>6 months). We investi-
gated the hemodynamic profile and exercise capacity in
LVAD patients who received pump speed optimization
following the mentioned approach.
Methods
Patients
Starting January 2009, all consecutive patients who under-
went LVAD implantation with the intention to bridge
them to transplantation were eligible for the study. As a
meaningful comparison of different LVAD systems is im-
possible, we included only patients with the Berlin Heart
INCOR® (Berlin Heart, Germany) operated at a rotor
speed according to a normal aortic valve function. A sec-
ond inclusion criterion was a support time of 6 months
without any major adverse event, and the ability to per-
form CPET.
The routine postimplantation protocol at our institu-
tion consists of monthly clinical examinations including
the driveline exit site, echocardiographic exam and a
cycle ergometry, as well as standard laboratory tests in-
cluding hemolytic parameters. Our institution recently
expanded the testing protocol by including CPET and a
sequential routine RHC at rest and on exercise. Data
were retrospectively analyzed and entered into a data-
base maintained within the section of Cardiac Surgery.
Informed consent for CPET and RHC as well as data
collection and anonymized reporting was obtained. Since
right heart catheterization belongs to our routine exami-
nations on LVAD support and due to the retrospective
nature of the study, formal approval by the institutional
review board was waived.
LVAD system, implantation and speed adjustment
All patients were provided with an INCOR® LVAD sys-
tem (Berlin Heart, Berlin, Germany), which is not avail-
able in the US but widely available in Europe and Asia.
The pump is equipped with silicone conduits and a
200 g titanium housing with an outer diameter of
30 mm containing an impeller with magnetic levitation
that avoids friction and wear. The rotor spins at 5,000 to
10,000 rpm and provides a flow between 3 and 10 liters
per minute. LVAD implantation was performed on a
beating heart via median sternotomy, and with the sup-
port of extracorporeal circulation. Cardiopulmonary
bypass was instituted with cannulation of the distalascending aorta and the right atrial appendage. The left
ventricular apex was elevated and a circular hole with a
coring knife were created. After careful inspection of the
left cavity 10 to 12 sutures reinforced by a Teflon felt
were placed around the access site. The sutures were led
through a Dacron ring, which was then connected to the
left ventricular apex. The inflow conduit was inserted
and fixed to the previously sutured Dacron ring. The
pump housing was connected and placed inside the peri-
cardial cavity above the heart, and the drive-line was
placed to exit the abdominal wall on the right upper
quadrant. The silicone outflow conduit was cut to an ap-
propriate length and sutured end-to-side to the ascend-
ing aorta with the help of a vascular side-biting clamp.
The pump was started after careful de-airing, and ad-
justed to provide a pump flow of 4 to 5 L/min, usually at
6,000 to 7,000 rpm. All silicone conduits are only avail-
able in one size, the length of the conduits are modifi-
able according to the anatomy of the patient.
Pump speed was optimized by monthly echocardio-
graphic monitoring with the aim to maintain an aortic
valve opening at least once every three heart beats with-
out any septal shifting at rest. In addition, patients
should be in NYHA class II and able to perform a sitting
cycle ergometer exercise of at least 10 minutes at a
workload of 20 Watts.
Cardiopulmonary exercise testing
We applied a standard CPET protocol on a sitting cycle
ergometer (Ergoselect 200, Ergoline, Bitz, Germany) with
breath-by-breath gas exchange measurements (Mas-
terScreen™ CPX, Care Fusion, Hoechberg, Germany) and
continuous monitoring of 12-lead ECG and oxygen sat-
uration by pulse oxymetry. Capillary blood was used for
lactate and gas analysis at rest and maximal exercise.
Due to the markedly reduced pulsatile blood flow in the
majority of patients, blood pressure measurements were
not carried out routinely by the means of ultrasound in a
systematic fashion. After 3 minutes of rest and 3 minutes
of unloaded cycling, workload was increased by 1 Watt
every 6 seconds, resulting in a ramp of 10 Watts/minute.
Exercise was symptom-limited or stopped after objective
withdrawal criteria were met. Exercise limiting symptoms
and dyspnea according to a 10-point Borg scale were re-
corded. Breath-by-breath data were averaged every 8
breaths and displayed according to Wasserman. The an-
aerobic threshold was determined by the V-slope method.
Right heart catheterization
RHC was performed the day after CPET or at the same
day after at least 2 hours of resting on an outpatient
basis. Patients were placed in a semi-recumbent position
on a lying cycle ergometer (Ergo-metrics 900, Ergoline,
Bitz, Germany). The pressure transducer was zeroed at
Table 1 Demographics
LVAD patients (n = 8)
General Data
Age, years 45 ± 13
Height, cm 174 ± 6
Weight, kg 75 ± 10
Body mass index, kg/m2 24 ± 3
LVEF, % 29 ± 11
Male 8




ACE inhibitors 7 (88%)
ß-blockers 7 (88%)
Diuretics 8 (100%)
Aldosteron antagonists 8 (100%)






Duration of LVAD support, days 465 ± 257
Pump flow, L/min 4 ± 0.3
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French Swan-Ganz-catheter (Edwards Lifesciences, Irvine,
CA, USA) was introduced via a cubital vein (8.5 French
sheath, Arrow, Reading, PA, USA) and forwarded into the
pulmonary artery by observation of the typical pressure
loops. Only in difficult cases fluoroscopy was used for
catheter placement. We recorded mean right atrial pres-
sure, systolic and end-diastolic right ventricular pressure,
systolic and diastolic pulmonary artery pressure (PAP),
and pulmonary artery wedge pressure (PAWP) at the end
of a patient’s normal expiration without using breath-hold
commands. Cardiac output was obtained by thermodilu-
tion averaging three measurements with a maximum devi-
ation of 10%. Measurements were carried out after at least
10 minutes of rest after the catheter placement and at a
constant work rate of 20 Watts after PAPs and heart
rate stabilized. Pulmonary vascular resistance (PVR)
was calculated as (mean PAP-PAWP)/cardiac output ×
80 [dyn*s*cm−5]. Mixed venous oxygen saturation was
determined by blood gas analysis from the pulmonary
artery at rest and the end of steady state exercise.
Statistical analysis
Results are expressed as means ± standard deviations.
The normality of distribution of quantitative variables
was verified with a Kolgomorov-Smirnov test. Compari-
sons of baseline data with exercise data were performed
using the t-test for paired values. Statistical significance
was defined at a p < 0.05. All analyses were performed
using SPSS 17 software (SPSS Inc, Chicago, IL).
Results
Patient characteristics
Since January 2009, 45 consecutive patients received an
LVAD at our institution, and 13 patients were success-
fully bridged to transplant. After the amendment of our
postimplantation monitoring program in January 2012
including CPET and RHC, 21 consecutive patients were
seen on an outpatient basis. After exclusion of 11 patients
(4 patients other LVAD device, 7 patients unable to per-
form exercise testing), 10 patients were eligible for the
study. Of these, one patient did not provide consent for
the invasive procedures, and in one patient RHC was not
possible due to difficult vascular access. The remaining 8
patients had a mean age of 45 ± 13 years with a mean sup-
port time of 465 ± 257 days at the time of exercise testing,
and a mean pump support of 4.0 ± 0.3 l/min at a speed of
6800–7100 rpm. The underlying diagnoses were dilative
cardiomyopathy in 6 patients and ischemic cardiomyop-
athy in 2 patients. All included patients were on an out-
patient basis in NYHA class 2. Echocardiography on
support at the time of exercise testing showed a mean left
ventricular ejection fraction (according to Simpson) of
29 ± 11%, and aortic valve opening was present at leastonce every three heart beats in all patients at rest. All but
one patient were in sinus rhythm at the time of the study.
To date all patients are still alive and in a good general
condition, and three patients were transplanted during the
study period. Further baseline characteristics are shown in
Table 1.
CPET
All patients underwent CPET without adverse events.
After a mean exercise time on CPET of 6.0 ± 1.2 minutes,
patients reached 69 ± 13 Watts (35 ± 7% predicted). Sub-
jective reason for exercise limitation was dyspnoea in all
patients with a median level on the Borg dyspnea scale
of 3 (range 2–4). All patients exercised above the anaer-
obic threshold reaching respiratory exchange rates on
exercise > 1 in all but one patient, and the mean respira-
tory exchange rate increased further after exercise to a
maximum of 1.25 ± 0.11. The lactate concentration in-
creased significantly from 9 ± 2 mg/dL to 40 ± 24 mg/dL
(p = 0.006). All patients showed a typical pattern of
cardiac limitation. The mean oxygen uptake (VO2) at
the anaerobic threshold and at peak exercise (Peak
VO2) was markedly reduced with 7.8 ± 1.3 mL/min/kg
(24 ± 6% of predicted peak VO2) and 12 ± 2 mL/min/kg
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ventilation to carbon dioxide output (VE/VCO2-slope)
was 42.3 ± 11.7. Further CPET variables are displayed
in Table 2.
Right heart catheterization
RHC was successful in all patients without adverse
events. All patients were able to perform a complete
steady state exercise at 20 Watts without the perception
of exertion or dyspnoea. Cardiac output increased moder-
ately from 4.7 ± 0.5 L/min to 6.2 ± 1.0 L/min (p = 0.008),
and so did heart rate from 83 ± 9.8 beats/min to 102 ±
13.4 beats/min (p = 0.02). All evaluated pressures in-
creased significantly performing the steady state low
work load exercise. Right atrial pressure increased from
5 ± 1.1 mmHg to 11 ± 3.6 mmHg (p =0.007), mean PAP in-
creased from 16 ± 2.4 mmHg to 27 ± 2.8 mmHg (p < 0.001),
and PAWP increased from 9 ± 3.3 mmHg to 17 ±
5.3 mmHg (p = 0.01). PVR increased slightly from 117 ±
35.4 dyn*sec*cm−5 to 125 ± 35.1 dyn*sec*cm−5 (p = 0.58).
Systemic vascular resistance could be evaluated in two
patients, since blood pressure was not reliably measur-
able in all patients, and in these two patients it de-
creased from 1084 ± 210.5 dyn*sec*cm−5 to 678 ±
26.5 dyn*sec*cm−5. Mean mixed venous oxygen satur-
ation decreased significantly from 58 ± 6% to 32 ± 9%
(p < 0.001). Further hemodynamics are depicted in
Figure 1.
Discussion
This study was the first evaluation of maximal CPET
and invasive hemodynamics under exercise on left ven-
tricular support with a speed adjustment according to
aortic valve opening. The results can be summarized as
follows: The maximum work load on CPET was ap-
proximately 70 Watts which is roughly 35% of predicted.Table 2 CPET
Parameter Observed % Predicted
Max. work load, Watt 69 ± 14 35 ± 7
HR at peak exercise, min−1 125 ± 24 72 ± 12
Max. O2-pulse, mL 8.1 ± 1.5 52 ± 7
VO2 at AT, mL/min 631 ± 120
24 ± 6*
VO2 at AT, mL/min/kg 7.8 ± 1.3
VO2 at peak exercise, mL/min 1004 ± 233
38 ± 8
VO2 at peak exercise, mL/min/kg 12.4 ± 2.5
VE/VCO2-slope 42.3 ± 11.7 -
BR at peak exercise, % 49 ± 15 > 20
Oxygen saturation at rest, % 97.1 ± 1.3 -
Oxygen saturation at peak exercise, % 96.2 ± 1.1 -
* % of predicted Peak-VO2.
BR = breathing reserve; HR = heart rate; VCO2 = carbon dioxide output;
VE = ventilation per minute; VO2 = oxygen uptake.Correspondingly, the mean peak VO2 was markedly re-
duced. Importantly, patients exercised until exhaustion
as reflected by the increase in arterial lactate concentra-
tion and respiratory exchange ratio. Interestingly, all pa-
tients were able to perform a complete steady state
exercise at 20 Watts without the perception of exertion
or dyspnoea. However, given the very low work rate se-
curely below the anaerobic threshold corresponding to
approximately 35% of predicted maximal work rates, in-
creases in PAWP and PAP are clearly above the physiologic
response reflecting left ventricular failure on exercise. The
severity of cardiac impairment is also reflected by the only
moderate increase in cardiac output and the marked de-
cline in mixed venous oxygen saturation. Of note is also
the clinically unapparent but low baseline mixed venous
saturation of 58% as a sign of controlled marginal support
due to the open aortic valve support policy in this patient
cohort. Adaptive and compensatory mechanisms in this
chronic heart failure population may explain the clinically
unapparent marginal support.
In order to interpret the RHC results under LVAD
support properly, a comparison with hemodynamics of
healthy subjects needs to be done, since no control
group with full support is available. In healthy individ-
uals older than 50 years an increase of PAWP and left
heart enddiastolic pressures under exercise seems to be
physiologic [10,11], and it is a physiologic behaviour that
the PVR slightly decreases under exercise [10]. The
LVAD population of this study displayed an increase in
PAWP comparable to healthy adults aged older than
50 years [10], but at the same time and different to
healthy subjects an increase in PVR. The missing de-
crease in PVR can be explained partially by irreversible
remodelling processes of the pulmonary vascular bed
due to long lasting left heart failure, and the marginal
support policy of the presented patient population
resulting in only a minor increase in cardiac output dur-
ing exercise [12]. The PAWP increase under exercise
was also seen by Maybaum et al. in patients with an
ejection fraction of 40% on support and on an outpatient
basis with PAWP values of 15 mmHg on an acute reduc-
tion of pump flow to 2–3 L/min according to their
weaning protocol [13].
Previous reports of exercise capacity in patients with
LVADs are mostly from relatively young patients im-
planted under the concept of bridge to transplantation
[8,14]. Leibner et al. monitored the exercise capacity by
repetitive peak VO2 measurements in a cfLVAD popula-
tion similar to our cohort before and at certain time
points up to 1 year after implantation of cfLVADs. Sur-
prisingly, no statistical improvement in peak VO2 at any
time point after implantation was noted with a mean
peak VO2 around 12 ml/min/kg similar to our values.
These findings raise the question whether peak VO2
Figure 1 Synopsis of the results. Abbr.: PCW= pulmonary capillary wedge pressure; RA = right atrial pressure; PA [mmHg] = pulmonary artery
pressure; RR = blood pressure (in 2 patients), PVR = pulmonary vascular resistance; SVR = systemic vascular resistance, PA [%] =mixed venous saturation,
* = significant difference from baseline (p < 0.05).
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cfLVAD patients, since clinically significant improve-
ments are observed. On the other hand, Jakovljevic et al.
reported an improvement after LVAD implantation with
a peak VO2 of 19.8 ± 5.8 ml/min/kg for patients sup-
ported with cfLVAD at the Harefield Hospital in the UK,
which is much higher than that measured in our patient
population. This discrepancy can be explained by a
younger age of the population (39 y vs. 45 y), in which
LVAD weaning was considered and a high left ventricu-
lar ejection of 50% compared to 30% in our patient
population [15,16]. Jacquet et al. reported a maximum
workload sustained by cfLVADs of 68 Watts with a peakVO2 of 15.8 mL/min/kg at a pump flow of 5.2 L/min.
[17]. Mancini et al. found similar values for peak VO2
and peak exercise in pulsatile devices [18]. Haft et al.
showed that pulsatile and continuous flow LVADs lead
to similar exercise capacities at higher flows compared
to our study population, demonstrating peak VO2 of ap-
proximately 15 mL/min/kg [8].
RHC still built the gold standard to accurately evaluate
hemodynamics. However, RHC is invasive with a risk of
adverse events explaining the scarcity of RHC on LVAD
support in general and under exercise even more. We
decided to include RHC utilizing the cubital vein with-
out discontinuation of anticoagulation at least once into
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able measurement of cardiac output and more important
PAPs, since pump speed is opted to be as low as possible
for several reasons. The main reason is a normal physi-
ology of the aortic valve to prevent deleterious aortic re-
gurgitation or thrombus formation [19]. Other reasons
to adjust pump speed to a an opening aortic valve are a
decrease of the likelihood of suction alarms by avoiding
full emptying of the left ventricle resulting in less blood
trauma due to reduced sheer stress [20]. Therefore, our
institutional policy is a rather low pump support (e.g.
4 L/min in the presented patient cohort). This policy
seems to be of growing interest, since devices are more
and more used in aged patients as destination therapy or
for longer periods of time [5,21,22]. Also partial support
devices seem to be a real alternative to the existing full
support devices on the market [20,23]. This strategy is
supported by similar CPET capacities under this sub-
maximal support and an open aortic valve policy com-
pared to previous invasive exercise studies of LVAD
patients on higher LVAD support levels. Remarkably, al-
though exercise capacity and hemodynamics were mark-
edly impaired, the patient population of this study was
clinically stable in NYHA 2 on an out-patient basis.
However, the effects of this submaximal support policy
on long-term outcome are yet unclear.
Limitations
There are certain limitations associated to this study.
First of all, a single institutional experience is reported
in a retrospective manner, and only one device in a small
but homogeneous group of patients was tested. Other
pumps might have a different impact on hemodynamics
during exercise, because of a different preload and after-
load behaviour. However, our institution mainly im-
plants the INCOR® Berlin Heart, therefore we included
only patients with this device to exclude device related
impacts on exercise performance. The next step will be
to systematically evaluate hemodynamic consequences
of exercise in other devices (e.g. centrifugal pumps vs.
axial pumps). Further, the near normal functioning of
the aortic valve was only checked on routine echocardio-
grams every 4 weeks and not immediately before and
during exercise.
No control group was tested to see whether higher
support levels lead to higher exercise capacities or im-
proved hemodynamics. There are several reasons for
this. First, our open aortic valve policy applies to all of
our LVAD patients. Therefore, a control population can’t
be generated out of our institution. The same population
could be a control with higher pump flows. However, we
decided not to set the pump speed higher and to per-
form the same exercise test, since patients were clinically
stable and setting the pump speed higher leads tosignificant more suction alarms, which we wanted to
avoid in this outpatient population. A systematic blood
pressure measurement was not performed since ultra-
sound was not available for each included patient. In
addition simultaneous pump flow measurements in
order to evaluate native cardiac function more appropri-
ate is missing. However, since the remaining cardiac
function interacts with pump flow detailed measure-
ments of flows on LVAD were not performed.Conclusion
The presented study has shown that a submaximal
LVAD support in order to keep a near physiologic aortic
valve function seems to be feasible with regard to “clin-
ical” exercise capacity as reflected by NYHA-class. How-
ever, maximal exercise capacity and hemodynamics
under submaximal LVAD support are still significantly
impaired. Adaptive mechanisms in long term LVAD sup-
port seem to compensate submaximal support leading to
clinically less impaired exercise capacity. These mecha-
nisms are unclear and not explained by this study. Further
studies are necessary to reveal them and to determine the
impact of our findings on long-term outcome.
Abbreviations
cfLVAD: Continuous flow left ventricular assist device; L/min: Liters per
minute; CPET: Maximal cardiopulmonary exercise testing; RHC: Right heart
catheterization; NYHA class: New York Heart Association functional
classification; VO2: Oxygen uptake; PVR: Pulmonary vascular resistance;
PAWP: Pulmonary artery wedge pressure; PAP: Pulmonary artery pressure;
RPM: Rounds per minute.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DC, data collection, exercise testing, and presentation of the data as text and
writing. TJL, data collection, exercise testing and presentation of the data as
text and writing. PG, Data aqusition, Echocardiography, patient care, proof
reading of the manuscript. SH, patient care, helped to draft the manuscript.
BF, Echocardiography, patient care, proof reading of the manuscript. YZ,
Anesthesia, helped to draft the manuscript. LR, Implanting surgeon, patient
care, helped to draft the manuscript. MH, Implanting surgeon, patient care,
helped to draft the manuscript. CS, Implanting surgeon, patient care,
participated in the design of the study, helped to draft the manuscript,
correction of the manuscript, comments to the reviewers. All authors read
and approved the final manuscript.
Acknowledgements
Birgit Heuschneider, Carola Krempl, and Vera Oelve for managing and timing
of the exams.
Author details
1Department of Cardiothoracic Surgery, University Medical Center
Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany.
2Department of Internal Medicine II/Pneumology, University Medical Center,
Regensburg, Germany. 3Department of Anesthesiology, University Medical
Center Regensburg, Regensburg, Germany.
Received: 9 January 2014 Accepted: 12 May 2014
Published: 20 May 2014
Camboni et al. Journal of Cardiothoracic Surgery 2014, 9:93 Page 7 of 7
http://www.cardiothoracicsurgery.org/content/9/1/93References
1. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky,
Long JW, Aschheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan
NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens
P, OZ MC, Poirier VL: Long-term use of a left ventricular assist device for
end-stage heart failure. N Engl J Med 2001, 345(20):1435–1443.
2. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG,
Naka Y, Mancini D, Miller LW: Outcomes of left ventricular assist device
implantation as destination therapy in the post-REMATCH era:
implications for patient selection. Circulation 2007, 116(5):497–505.
3. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, Conte JV,
Bogaev RC, MacGilivray TE, Naka Y, Mancini D, Massey HT, Chen L, Klodell
CT, Aranda JM, Moazami N, Ewald GA, Farrar DJ, Frazier OH: Extended
mechanical circulatory support with a continuous-flow rotary left
ventricular assist device. J Am Coll Cardiol 2009, 54(4):312–321.
4. Adamson RM, Dembitsky WP, Baradarian S, Chammas J, May-Newman K,
Chillcott S, Stahovich M, McCalmont V, Ortiz K, Hoagland P, Jaski B: Aortic
valve closure associated with HeartMate left ventricular device support:
technical considerations and long-term results. J Heart Lung Transplant
2011, 30(5):576–582.
5. John R, Mantz K, Eckman P, Rose A, May-Newman K: Aortic valve
pathophysiology during left ventricular assist device support. J Heart
Lung Transplant 2010, 29(12):1321–1329.
6. Connelly JH, Abrams J, Klima T, Vaughn WK, Frazier OH: Acquired
commissural fusion of aortic valves in patients with left ventricular assist
devices. J Heart Lung Transplant 2003, 22(12):1291–1295.
7. Uriel N, Morrison KA, Garan AR, Kato TS, Yuzefpolskaya M, Latif F, Restaino
SW, Mancini DM, Flannery M, Takayama H, John R, Colombo PC, Naka Y,
Jorde UP: Development of a novel echocardiography ramp test for speed
optimization and diagnosis of device thrombosis in continuous-flow left
ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol 2012,
60(18):1764–1775.
8. Haft J, Armstrong W, Dyke DB, Aaronson KD, Koelling TM, Farrar DJ, Pagani
FD: Hemodynamic and exercise performance with pulsatile and
continuous-flow left ventricular assist devices. Circulation 2007,
116(11 Suppl):I8–I15.
9. Mancini DM, Beniaminovitz A, Levin H, Catanese K, Flannery M, DiTullio M,
Savin S, Cordisco ME, Rose E, Oz M: Low incidence of myocardial recovery
after left ventricular assist device implantation in patients with chronic
heart failure. Circulation 1998, 98(22):2383–2389.
10. Kovacs G, Olschewski A, Berghold A, Olschewski H: Pulmonary vascular
resistances during exercise in normal subjects: a systematic review. Eur
Respir J 2012, 39(2):319–328.
11. Ehrsam RE, Perruchoud A, Oberholzer M, Burkart F, Herzog H: Influence of
age on pulmonary haemodynamics at rest and during supine exercise.
Clin Sci 1983, 65(6):653–660.
12. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE,
Gomberg-Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza
R: World Health Organization Pulmonary Hypertension group 2:
pulmonary hypertension due to left heart disease in the adult–a
summary statement from the Pulmonary Hypertension Council of the
International Society for Heart and Lung Transplantation. J Heart Lung
Transplant 2012, 31(9):913–933.
13. Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, Miller
LW, Margulies K, McRee S, Frazier OH, Torre-Amione G: Cardiac improvement
during mechanical circulatory support: a prospective multicenter study of
the LVAD Working Group. Circulation 2007, 115(19):2497–2505.
14. Meyns BP, Simon A, Klotz S, Wittwer T, Schlensak C, Rega F, Burkhoff D:
Clinical benefits of partial circulatory support in New York Heart
Association Class IIIB and Early Class IV patients. Eur J Cardiothorac Surg
2011, 39(5):693–698.
15. Jakovljevic DG, George RS, Donovan G, Nunan D, Henderson K, Bougard RS,
Yacoub MH, Birks EJ, Brodie DA: Comparison of cardiac power output and
exercise performance in patients with left ventricular assist devices,
explanted (recovered) patients, and those with moderate to severe heart
failure. Am J Cardiol 2010, 105(12):1780–1785.
16. Jakovljevic DG, George RS, Nunan D, Donovan G, Bougard RS, Yacoub MH,
Birks EJ, Brodie DA: The impact of acute reduction of continuous-flow left
ventricular assist device support on cardiac and exercise performance.
Heart 2010, 96(17):1390–1395.17. Jacquet L, Vancaenegem O, Pasquet A, Matte P, Poncelet A, Price J, Gurné
O, Noirhomme P: Exercise capacity in patients supported with rotary
blood pumps is improved by a spontaneous increase of pump flow at
constant pump speed and by a rise in native cardiac output. Artif Organs
2011, 35(7):682–690.
18. Mancini D, Goldsmith R, Levin H, Beniaminovitz A, Rose E, Catanese K,
Flannery M, Oz M: Comparison of exercise performance in patients with
chronic severe heart failure versus left ventricular assist devices.
Circulation 1998, 98(12):1178–1183.
19. Pak S, Uriel N, Takayama H, Cappleman S, Song R, Colombo PC, Charles S,
Mancini D, Gillam L, Naka Y, Jorde UP: Prevalence of de novo aortic
insufficiency during long-term support with left ventricular assist
devices. J Heart Lung Transplant 2010, 29(10):1172–1176.
20. Slaughter MS: Hematologic effects of continuous flow left ventricular
assist devices. J Cardiovasc Transl Res 2010, 3(6):618–624.
21. Slaughter MS: Long-term continuous flow left ventricular assist device
support and end-organ function: prospects for destination therapy.
J Card Surg 2010, 25(4):490–494.
22. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, Ewald
GA, Sundareswaran KS, Farrar DJ, Slaughter MS: Outcomes in advanced
heart failure patients with left ventricular assist devices for destination
therapy. Circ Heart Fail 2012, 5(2):241–248.
23. Klotz S, Meyns B, Simon A, Wittwer T, Rahmanian P, Schlensak C, Tjan TT,
Scheld HH, Burkhoff D: Partial mechanical long-term support with the
CircuLite Synergy pump as bridge-to-transplant in congestive heart
failure. Thorac Cardiovasc Surg 2010, 58(Suppl 2):S173–S178.
doi:10.1186/1749-8090-9-93
Cite this article as: Camboni et al.: Left ventricular support adjustment
to aortic valve opening with analysis of exercise capacity. Journal of
Cardiothoracic Surgery 2014 9:93.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
